Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Regeneron Pharmaceuticals Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $74.9B | |
|---|---|---|
| P/E (forward) | 13.3x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | — | $12.17B | $13.12B | $14.20B | $14.34B | +5.6% |
| Gross profit | — | $10.61B | $11.30B | $12.23B | $12.24B | +4.9% |
| Operating income | — | $4.92B | $4.27B | $4.84B | $5.27B | +2.4% |
| Net income | — | $4.34B | $3.95B | $4.41B | $4.50B | +1.3% |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | -12.9% |
| EBITDA | — | $5.26B | $4.69B | $5.32B | $5.82B | +3.4% |
| R&D | — | $3.85B | $4.63B | $5.23B | $5.85B | +15.0% |
| SG&A | — | $2.12B | $2.63B | $2.95B | $2.70B | +8.5% |
Recent company headlines from major financial publishers.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.6% | $1,545 | $1,793 | $2,117 | $2,117 | $2,117 |
| 6.6% | $1,210 | $1,357 | $1,545 | $1,793 | $2,117 |
| 7.6% | $994 | $1,091 | $1,210 | $1,357 | $1,545 |
| 8.6% | $844 | $913 | $994 | $1,091 | $1,210 |
| 9.6% | $733 | $784 | $844 | $913 | $994 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
